Comparison of the efficacy of Iressa and cabozantinib: Which one is better?

Iressa and cabozantinib are both drugs used to treat cancer, but their efficacy, mechanisms of action and indications are different. Iressa, gefitinib tablets, is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It mainly targets specific mutations on EGFR, especially for patients with locally advanced or metastatic non-small cell lung cancer who have received chemotherapy. Iressa can inhibit the growth and spread of tumor cells, and also has certain analgesic and anti-inflammatory effects. However, the efficacy of Iressa is mainly limited to patients with EGFR mutations, and may not be effective for other types of tumors or patients without EGFR mutations.

Cabozantinib is a multi-target tyrosine kinase inhibitor with as many as 9 targets, including MET, VEGFR2, RET, etc. By inhibiting the activity of these kinases, it plays an anti-tumor role, delays tumor development and metastasis, and inhibits the neogenesis of tumor blood vessels. Cabozantinib has a wider range of indications, including liver cancer, thyroid cancer, renal cancer, non-small cell lung cancer and other solid tumors. In some studies, cabozantinib has shown good efficacy as a monotherapy or in combination with other drugs, including in patients with wild-type EGFR NSCLC. In addition, cabozantinib also has significant efficacy in patients with bone metastases.

Iressa and cabozantinib each have their own advantages. Iressa has a significant effect on patients with EGFR mutated non-small cell lung cancer, and can effectively control the disease and prolong survival. However, its efficacy is relatively limited, mainly targeting patients with EGFR mutations. In contrast, due to its multi-target properties, cabozantinib has potential application value in the treatment of a variety of tumors and has wider indications. Therefore, when choosing which drug is better, the decision needs to be based on the patient's specific situation and tumor type. For patients with non-small cell lung cancer with EGFR mutations, Iressa may be a more suitable choice; for other types of tumors or situations where multi-target inhibition is required, cabozantinib may have more advantages.